Interferon regulatory factor-5-regulated pathways as a target for colorectal cancer therapeutics

References

• Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J. Clin.54, 8–29 (2004).
   PubMed Web of Science ®Google Scholar
• McWilliams RA, Erlichman C. Novel therapeutics in colorectal cancer. Dis. Colon Rectum48, 1632–1650 (2005).
   PubMedGoogle Scholar
• Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med.343, 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• Graeven U, Andre N, Schmiegel W. Colorectal cancer: current treatment options. Z. Gastroenterol.42, 1399–1407 (2004).
   PubMedGoogle Scholar
• Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet355, 1041–1047 (2000).
   PubMed Web of Science ®Google Scholar
• Awada A, Mano M, Hendlisz A, Piccart M. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective. Expert Rev. Anticancer Ther.4, 53–60 (2004).
   PubMedGoogle Scholar
• Miyamoto M, Fujita T, Kimura Y et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-β gene regulatory elements. Cell54, 903–913 (1988).
   PubMed Web of Science ®Google Scholar
• Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev.8, 293–312 (1997).
   PubMedGoogle Scholar
• Mamane Y, Heylbroeck C, Genin P et al. Interferon regulatory factors: the next generation. Gene237, 1–14 (1999).
   PubMed Web of Science ®Google Scholar
• Harada H, Taniguchi T, Tanaka N. The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie80, 641–650 (1998).
   PubMed Web of Science ®Google Scholar
• Barnes BJ, Lubyova B, Pitha PM. On the role of IRF in host defense. J. Interferon Cytokine Res.22, 59–71 (2002).
   PubMed Web of Science ®Google Scholar
• Tanaka N, Ishihara M, Lamphier MS et al. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature382, 816–818 (1996).
   PubMed Web of Science ®Google Scholar
• Tanaka N, Ishihara M, Kitagawa M et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell77, 829–839 (1994).
   PubMed Web of Science ®Google Scholar
• Tamura T, Ishihara M, Lamphier MS et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature376, 596–599 (1995).
   PubMed Web of Science ®Google Scholar
• Pamment J, Ramsey E, Kelleher M, Dornan D, Ball KL. Regulation of the IRF-1 tumor modifier during the response to genotoxic stress involves an ATM-dependent signaling pathway. Oncogene21, 7776–7785 (2002).
   PubMed Web of Science ®Google Scholar
• Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, Arakawa H. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene21, 2914–2918 (2002).
   PubMed Web of Science ®Google Scholar
• Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res.63, 6424–6431 (2003).
   Google Scholar
• Hu G, Marcl ME, Barnes BJ. Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res.65, 7403–7412 (2005).
   PubMed Web of Science ®Google Scholar
• Tanaka N, Kawakami T, Taniguchi T. Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system. Mol. Cell Biol.13, 4531–4538 (1993).
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science264, 1415–1421 (1994).
   PubMed Web of Science ®Google Scholar
• Driggers PH, Ennist DL, Gleason SL et al. An interferon γ-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc. Natl Acad. Sci. USA87, 3743–3747 (1990).
   PubMed Web of Science ®Google Scholar
• Goodbourn S, Zinn K, Maniatis T. Human β-interferon gene expression is regulated by an inducible enhancer element. Cell41, 509–520 (1985).
   PubMedGoogle Scholar
• Goodbourn S, Maniatis T. Overlapping positive and negative regulatory domains of the human β-interferon gene. Proc. Natl Acad. Sci. USA85, 1447–1451 (1988).
   PubMedGoogle Scholar
• Fujii Y, Shimizu T, Kusumoto M, Kyogoku Y, Taniguchi T, Hakoshima T. Crystal structure of an IRF-DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences. EMBO J.18, 5028–5041 (1999).
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol.19, 623–655 (2001).
   PubMed Web of Science ®Google Scholar
• Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol. Cell. Biol.22, 5721–5740 (2002).
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Suhara W, Fujita T. Control of IRF-3 activation by phosphorylation. J. Interferon Cytokine Res.22, 73–76 (2002).
   PubMed Web of Science ®Google Scholar
• Reich NC. Nuclear/cytoplasmic localization of IRFs in response to viral infection or interferon stimulation. J. Interferon Cytokine Res.22, 103–109 (2002).
   PubMedGoogle Scholar
• Watanabe N, Sakakibara J, Hovanessein AG, Taniguchi T, Fujita T. Activation of IFN-β element by IRF-1 requires a posttranslational event in addition to IRF-1 synthesis. Nucleic Acids Res.19, 4421–4428 (1991).
   PubMed Web of Science ®Google Scholar
• Au WC, Moore PA, LaFleur DW, Tombal B, Pitha PM. Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. J. Biol. Chem.273, 29210–29217 (1998).
   PubMed Web of Science ®Google Scholar
• Lin R, Heylbroeck C, Pitha PM, Hiscott J. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol.18, 2986–2996 (1998).
   PubMed Web of Science ®Google Scholar
• Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon αgenes. J. Biol. Chem.276, 23382–23390 (2001).
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J.17, 1087–1095 (1998).
   PubMed Web of Science ®Google Scholar
• Caillaud A, Prakash A, Smith E et al. Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding. J. Biol. Chem.277, 49417–49421 (2002).
   PubMed Web of Science ®Google Scholar
• Iwamura T, Yoneyama M, Yamagachi K et al. Induction of IRF-3/-7 kinase and NF-κB in response to double-stranded RNA and virus infection: common and unique pathways. Genes Cells 6, 375–388 (2001).
   PubMed Web of Science ®Google Scholar
• Au WC, Pitha PM. Recruitment of multiple interferon regulatory factors and histone acetyltransferase to the transcriptionally active interferon a promoters. J. Biol. Chem.276, 41629–41637 (2001).
   PubMed Web of Science ®Google Scholar
• Izaguirre A, Barnes BJ, Amrute S et al. Comparative analysis of IRF and IFN-α expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc. Biol.74, 1125–1138 (2003).
   PubMed Web of Science ®Google Scholar
• Barnes BJ, Field AE, Pitha PM. Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. J. Biol. Chem.278, 16630–16641 (2003).
   PubMed Web of Science ®Google Scholar
• Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J. Biol. Chem.279, 45194–45207 (2004).
   PubMed Web of Science ®Google Scholar
• Mancl ME, Hu G, Sangster-Guity N et al. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. J. Biol. Chem.280, 21078–21090 (2005).
   PubMed Web of Science ®Google Scholar
• Schoenemeyer A, Barnes BJ, Mancl ME et al. The interferon regulatory factor, IRF-5, is a central mediator of Toll-like receptor 7 signaling. J. Biol. Chem.280, 17005–17012 (2005).
   PubMed Web of Science ®Google Scholar
• Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-α genes by positive feedback through interferon regulatory factor-7. EMBO J.17, 6660–6669 (1998).
   PubMed Web of Science ®Google Scholar
• Juang YT, Lowther W, Kellum M et al. Primary activation of interferon A and interferon B gene transcription by interferon regulatory factor 3. Proc. Natl Acad. Sci. USA95, 9837–9842 (1998).
   PubMed Web of Science ®Google Scholar
• Fitzgerald KA, Rowe DC, Barnes BJ et al. LPS-TLR4 signaling to IRF-3/7 and Nf-κB involves the Toll adapters TRAM and TRIF. J. Exp. Med.198, 1043–1055 (2003).
   PubMed Web of Science ®Google Scholar
• Morin P, Braganca J, Bandu MT et al. Preferential binding sites for interferon regulatory factors 3 and 7 involved in interferon-A gene transcription. J. Mol. Biol.316, 1009–1022 (2002).
   PubMed Web of Science ®Google Scholar
• Takaoka A, Yanai H, Kondo S et al. Integral role of IRF-5 in the gene induction programme activated by toll-like receptors. Nature434, 243–249 (2005).
   PubMed Web of Science ®Google Scholar
• Hayashida S, Yamasaki K, Asada Y, Soeda E, Niikawa N, Kishino T. Construction of a physical and transcript map flanking the imprinted MEST/PEG1 region at 7q32. Genomics66, 221–225 (2000).
   PubMedGoogle Scholar
• Oscier DG, Gardiner A, Mould S. Structural abnormalities of chromosome 7q in chronic lymphoproliferative disorders. Cancer Genet. Cytogenetics92, 24–27 (1996).
   PubMed Web of Science ®Google Scholar
• Mertens F, Johansson B, Hoglund M, Mitelman F. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res.57, 2765–2780 (1997).
   PubMed Web of Science ®Google Scholar
• Philips AV, Cooper TA. RNA processing and human disease. Cell. Mol. Life Sci.57, 235–249 (2000).
   PubMedGoogle Scholar
• Nissim-Rafinia M, Kerem B. Splicing regulation as a potential genetic modifier. Trends Genet.18, 123–127 (2002).
   PubMed Web of Science ®Google Scholar
• Bunz F, Dutriaux A, Lengauer C et al.Science282, 1497–1501 (1998).
   PubMed Web of Science ®Google Scholar
• Ravi R, Bedi A. Potential mechanisms to circumvent blocks in apoptosis in lymphomas. Curr. Opin. Oncol.14, 490–503 (2002).
   PubMedGoogle Scholar
• Yang J, Yu Y, Hamrick HE, Duerksen-Hughes PJ. ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis24, 1571–1580 (2003).
   PubMed Web of Science ®Google Scholar
• Yaffe MB, Leparc GG, Lai J, Obata T, Volinia S, Cantley LC. A motif-based profile scanning approach for genome-wide prediction of signaling pathways. Nat. Biotechnol.19, 348–353 (2001).
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Jensen RB, Kirchgessner CU. Complementation of the radiosensitive M059J cell line. Radiat. Res.153, 125–130 (2000).
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14–1, in human colon cancer cells. Clin. Cancer Res.10, 8284–8292 (2004).
   Google Scholar
• Gura T. How TRAIL kills cancer cells, but not normal cells. Science277, 768 (1997).
   PubMed Web of Science ®Google Scholar
• Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res.59, 6153–6158 (1999).
   PubMed Web of Science ®Google Scholar
• Kelley SK, Harris LA, Xie D et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther.299, 31–38 (2001).
   PubMed Web of Science ®Google Scholar
• Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients’ colon tumors grown in SCID mice. Cancer Res.62, 5800–5806 (2002).
   PubMed Web of Science ®Google Scholar
• Strater J, Walczak H, Pufrop T et al. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infection. Gastroenterol.122, 659–666 (2002).
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science281, 1305–1308 (1998).
   PubMed Web of Science ®Google Scholar
• Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell102, 1–4 (2000).
   PubMed Web of Science ®Google Scholar
• van Geelen CM, de Vries EG, Le TK, van Weeghel RP, de Jong S. Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br. J. Cancer.89, 363–373 (2003).
   PubMedGoogle Scholar
• Ravi R, Jain AJ, Schulick RD et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res.64, 9105–9114 (2004).
   PubMed Web of Science ®Google Scholar
• Nagane M, Huang HJ, Cavanee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis6, 191–197 (2001).
   PubMed Web of Science ®Google Scholar
• LeBlanc H, Lawrence D, Varfolomeev E et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med.8, 274–281 (2002).
   PubMed Web of Science ®Google Scholar
• Arizono Y, Yoshikawa H, Naganuma H, Hamada Y, Nakajima Y, Tasaka K. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents. Br. J. Cancer88, 298–306 (2003).
   PubMedGoogle Scholar
• Langaas V, Shahzidi S, Johnsen JI, Smedsrod B, Sveinbjornsson B. Interferon-γ modulates TRAIL-mediated apoptosis in human colon carcinoma cells. Anticancer Res.21, 3733–3738 (2001).
   PubMed Web of Science ®Google Scholar
• Green JE, Hudson T. The promise of genetically engineered mice for cancer prevention studies. Nat. Rev. Cancer5, 184–198 (2005).
   PubMed Web of Science ®Google Scholar